All In MedTech

FDA Clearance Tracker · P990025-S009

NAVISTAR RMT DIAGNOSTIC/ABLATION STEERABLE TIP CATHETER

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jan 26, 2006 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jan 26, 2006

Approved

Time to decision

274 days

Received Apr 27, 2005. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P990025-S009
Device name
NAVISTAR RMT DIAGNOSTIC/ABLATION STEERABLE TIP CATHETER
Applicant location
Irvine, CA
Received
Apr 27, 2005
Decided
Jan 26, 2006
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P990025

Device type

Device class
Class III

Every decision under product code LPB

FDA's approval statement

As written in FDA's record.

APPROVAL FOR ADDING REMOTE MAGNETIC NAVIGATION TECHNOLOGY TO THE PREVIOUSLY APPROVED CATHETER. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME NAVISTAR RMT DIAGNOSTIC/ABLATION STEERABLE TIP CATHETER AND IS INDICATED FOR CATHETER-BASED ATRIAL AND VENTRICULAR ELECTROPHYSIOLOGIC MAPPING AND FOR USE WITH THE STEREOTAXIS MAGNETIC NAVIGATION SYSTEM (MNS) AND COMPATIBLE RADIOFREQUENCY GENERATORS IN ADULTS AND CHILDREN FOUR (4) YEARS OF AGE OR OLDER IN CREATING ENDOCARDIAL LESIONS DURING CARDIAC ABLATION PROCEDURES TO TREAT ARRHYTHMIAS. WHEN USED WITH THE CARGO? EP NAVIGATION SYSTEM, THE NAVISTAR RMT CATHETER PROVIDES LOCATION INFORMATION.

Source documents

Other decisions for Biosense Webster, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.